Post-Menopausal Osteoporosis

2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
romosozumab HCP administration with PFSPhase 31 trial
Active Trials
NCT03432533Completed283Est. Jan 2020
M&
Merck & Co.RAHWAY, NJ
1 program
1
MK0429Phase 22 trials
Active Trials
NCT00302471Completed29Est. Oct 2007
NCT00533650Completed227Est. Oct 2002

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Amgenromosozumab HCP administration with PFS
Merck & Co.MK0429
Merck & Co.MK0429

Clinical Trials (3)

Total enrollment: 539 patients across 3 trials

NCT03432533Amgenromosozumab HCP administration with PFS

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

Start: Feb 2018Est. completion: Jan 2020283 patients
Phase 3Completed
NCT00533650Merck & Co.MK0429

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Start: Dec 2000Est. completion: Oct 2002227 patients
Phase 2Completed
NCT00302471Merck & Co.MK0429

MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)

Start: Mar 2006Est. completion: Oct 200729 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space